


Curriculum Vitae

| | | |
|---|--|---|
| Name | Shirish Madhav Gadgeel, M.D |  |
| Current Position & Affiliation | Division Chief, Hematology/Oncology, Henry Ford Cancer Institute/Henry Ford Health System | |
| Country | USA | |

Educational Background

| INSTITUTION AND LOCATION | DEGREE (if applicable) | Completion Date MM/YYYY | FIELD OF STUDY |
|--|-----------------------------------|------------------------------------|-----------------------------|
| University of Bombay, Bombay, India | M.B., B.S. | 1989 | Medicine and Surgery |
| University of Bombay, Bombay, India | MD/Residency | 01/1992 | Internal Medicine |
| Wayne State University, Detroit, MI | MD/Residency | 06/1996 | Internal Medicine |
| Wayne State University, Detroit, MI | MD/Fellowship | 06/1999 | Hematology/Oncology |
| Wayne State University, Detroit, MI | MD/Fellowship | 06/2000 | Bone Marrow Transplantation |

Professional Experience

- 2000 – 2006 Assistant Professor, Department of Internal Medicine, Division of Hematology and Oncology, Wayne State University School of Medicine/Karmanos Cancer Institute, Detroit, Michigan
- 2006 – 2013 Associate Professor, Department of Internal Medicine, Division of Hematology and Oncology, Wayne State University School of Medicine/Karmanos Cancer Institute, Detroit, Michigan

- 2009-2017 Leader of the Thoracic Oncology Program, Wayne State University, Karmanos Cancer Institute, Detroit, Michigan
- 2013-2017 Professor, Department of Oncology, Wayne State University, Detroit, Michigan
- 2017- 2020- Professor, Department of Internal Medicine, Co-Leader of the Thoracic Oncology Research Program, University of Michigan. Leader of the Multi-Tumor Experimental Therapeutic Team.
- 2020- Chief of Division of Hematology/Oncology, Henry Ford Cancer Institute/Henry Ford Hospital

Professional Organizations

- Present Member, American Society of Clinical Oncology
- Present Member, International Association for the Study of Lung Cancer
- 2005-present Steering Committee of the Experimental Therapeutics Committee and Lung Cancer Committee, Southwest Oncology Group (SWOG)
- 2012-2014 President of the Medical Staff Committee of Karmanos Cancer Hospital
- 2012-2017 Co-Leader, Molecular Therapeutics Program, Karmanos Cancer Center
- 2007-2012 Member of the Institutional Review Board of Wayne State University
- 2009-2011 Education Committee of the American Society of Clinical Oncology
- 2008-present Member of the Editorial Board of Clinical Lung Cancer and Cancer
- 2000-2017 Member of the Protocol Review Committee of Karmanos Cancer Institute
- 2015-present Member of the Ethics Committee, International Association for the Study of Lung Cancer
- 2015-2017 Member of the Cancer Education Committee, American Society of Clinical Oncology
- 2018-2019 Chair of the Ethics Committee, International Association for the Study of Lung Cancer
- 2019-present Member, Communications Committee, International Association for the Study of Lung Cancer

Main Scientific Publications

1. **Gadgeel S**, Rodriguez-Abreu D, Speranza, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. *J Clin Oncol* 2020;38:1505-17.
2. **Gadgeel SM**, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. *Lancet Oncol* 2014;15:1119-28. This was a Phase I trial of a novel ALK inhibitor. I was one of the PIs evaluating this drug in ALK positive lung cancer patients whose cancer was resistant to crizotinib.
3. Langer C, **Gadgeel SM**, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: randomized, phase 2 cohort of the open-label KEYNOTE-021 study. *Lancet Oncol* 2016;17:1497-1508. The above 2 studies were the first to show that addition of a PD-1 inhibitor to cytotoxic chemotherapy can improve outcomes. The results of these 2 studies established a new standard of care for the management of advanced non-squamous NSCLC.
4. **Gadgeel SM**, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A. Phase II study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) inhibitor, in Patients with Platinum Refractory Non-Small Cell Lung Cancer (NSCLC). *J Thorac Oncol* 2007;2:299-305. This was an investigator initiated trial based on laboratory research, some of which was conducted at our institution.
5. **Gadgeel S**, Graff J, Kau Y, Weiss L, Severson R, Kalemkerian GP. Racial differences in lung cancer: Analysis of the Metropolitan Detroit SEER database. *Chest* 2001;120:55-63. A detailed analysis of the SEER database to identify the clinical differences of lung cancer among African-American patients and Caucasian patients.

6. **Gadgeel SM**, Ventimiglia J, Kalemkerian G, Fidler MJ, Chen W, Sukari A, Halmos B, Boerner J, Wozniak AJ, Galasso C, Pennell N. Phase II study of maintenance pembrolizumab in extensive stage small cell lung cancer patients (NCT02359019). *J Thorac Oncol* 2018;13:1393-99. This was a PI initiated study supported by Merck. The study was among the first to evaluate an immune check point inhibitor as part of the front-line therapy in SCLC patients. The results of this study have formed the basis for ongoing trials with this drug in SCLC patients.

Bibliography- <http://www.ncbi.nlm.nih.gov/pubmed/?term=Gadgeel+S>
